Innovative therapy targeting antithrombin receives FDA approval for haemophilia A and B with or without inhibitors

Coagulation Profile BV extends its warm congratulations to Sanofi on the recent FDA approval of Qfitlia (fitusiran), an innovative therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes for adults and adolescents with haemophilia A or B with or without inhibitors [Link]. With its novel antithrombin-targeting mechanism of action, proven reductions in annual bleeding rates more than 70% in both haemophilia A and B with and without inhibitors, and convenient subcutaneous administration once every two months, Qfitlia is expected to become a game-changer for patients living with these haemophilias and their families.

We also congratulate Siemens Healthineers on receiving FDA clearance of the Innovance Antithrombin companion diagnostic test for use with Qfitlia [Link].

As a specialist provider of analytical and assay development services for the diagnosis and treatment of coagulation disorders, Coagulation Profile BV is proud to have been a trusted partner during the development of Qfitlia, supporting Sanofi with high-quality, reliable solutions tailored to the unique demands of this therapy. We are pleased that our contribution played a role in making this innovative therapy available to patients.

Coagulation Profile offers a portfolio of standard and custom-made coagulation marker assays available for preclinical and clinical research, developed by highly qualified and experienced scientists in the fields of thrombosis, haemophilia and vascular biology. Find out how your development programme can benefit from our broad experience and comprehensive knowledge by contacting info@coagulationprofile.com.